<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362895">
  <stage>Registered</stage>
  <submitdate>13/08/2012</submitdate>
  <approvaldate>28/08/2012</approvaldate>
  <actrnumber>ACTRN12612000920897</actrnumber>
  <trial_identification>
    <studytitle>A clinical trial to compare the pharmacokinetic and pharmacodynamic profile of two preparations of pegfilgrastim</studytitle>
    <scientifictitle>A Double-blind, Randomised, Controlled, 3 Cohort, Dose ranging, Crossover, Pharmacokinetic and Pharmacodynamic Study of Two Preparations of Pegfilgrastim in Healthy Subjects</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>The pharmacokinetic and pharmacodynamic profile of two preparations of pegfilgrastim in healthy volunteers</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Comparative Dose ranging study (comparing Dr Reddy's Labs [DRL's] pegfilgrastim &amp; Reference Medicinal Product [RMP] - Neulasta [registered trademark], a different preparation of pegfilgrastim)  in a single dose, cross over design with 28 days wash out, with 3 cohorts (30,60 &amp; 100mcg/kg by Subcutaneous [SC] injection). All participants at each dose cohort will receive both formulations of pegfilgrastim, 28 days apart.</interventions>
    <comparator>Neulasta. This is a comparative Dose ranging study (comparing DRL pegfilgrastim &amp; RMP - Neulasta [registered trademark])  in a single dose cross over design with 28 days wash out with 3 cohorts (30,60 &amp; 100mcg/kg SC)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of 2 preparations of pegfilgrastim; i.e., DRL pegfilgrastim and the RMP - Neulasta (registered trademark) from analysis of blood samples.</outcome>
      <timepoint>Time = 56 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare additional PD measures of cell response of DRL pegfilgrastim to the RMP-Neulasta (registered trademark) from analysis of blood samples.</outcome>
      <timepoint>Time = 56 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the immunogenicity of two preparations of pegfilgrastim from analysis of blood samples.</outcome>
      <timepoint>Time = 56 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Healthy male and female subjects
- In general good health
-Must have normal organ function; including normal liver and renal function 
-Non-smokers or ex-smokers who have not smoked within the previous 6 months from Screening visit.
-Subjects must be able to understand and willing to comply with the study procedures, restrictions and requirements as judged by the investigator.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>- Known hypersensitivity to Escherichia coli derived proteins and/or hypersensitivity to the study drug pegfilgrastim or filgrastim or any of its ingredients.
- History of hypersensitivity to latex.
- Any prior exposure to any peptide colony stimulating or growth factor, including erythropoietin, filgrastim or pegfilgrastim; or prior immunoglobulin preparations within the previous 6 months from Screening visit.
Hereditary fructose intolerance.
- Any clinically significant laboratory findings (haematology, biochemistry and urinalysis) outside the normal laboratory range of the test laboratory (where the test will be conducted).
- Any psychological, familial, sociological, personal (including out of town trips) or geographical conditions that do not permit compliance with the Clinical Study Protocol.
- Hypertension, significant hypercholesterolemia as judged by the investigator, or thyroid abnormalities.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All eligible healthy subjects will be randomized into 3 cohorts in this comparative dose ranging study  to receive DRL pegfilgrastim  and RMP Neulasta (registered trademark) in a cross over manner. All eligible healthy subjects will be randomized by an unblinded Pharmacist not involved in other trial activities, using a pre-defined code into 3 cohorts to receive study drug and RMP in a double blind cross over manner.</concealment>
    <sequence>Subjects will be equally randomized using a permuted block randomisation, stratified by age and gender into one of three dose cohorts, and equally randomized within cohorts for the two treatment sequence.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>5/10/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Dr. Reddy’s Laboratories (DRL)</primarysponsorname>
    <primarysponsoraddress>Survey No. 47, Bachupalli, Qutubullapur
R. R. Dist  500 090, Andhra Pradesh, India</primarysponsoraddress>
    <primarysponsorcountry>India</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Dr. Reddy's Laboratories (DRL)</fundingname>
      <fundingaddress>Survey No. 47, Bachupalli, Qutubullapur
R. R. Dist  500 090, Andhra Pradesh, India</fundingaddress>
      <fundingcountry>India</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Quintiles Pty. Ltd.</sponsorname>
      <sponsoraddress>Level 10  67 Albert Avenue
Chatswood, New South Wales 2067</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a crossover dose ranging study to assess and compare the PK/PD, immunogenicity and safety profiles of two preparations of Pegfilgrastim.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Hospital Research and Ethics Unit</ethicname>
      <ethicaddress>55 Commercial Road, Melbourne, Victoria 3004</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>23/07/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Shivkumar Madki, Dr. Reddy’s Laboratories (DRL)</name>
      <address>Survey No. 47, Bachupalli, Qutubullapur, R. R. Dist  500 090, Andhra Pradesh</address>
      <phone>+91-40-4464-4000</phone>
      <fax>+91-40-2304-1418</fax>
      <email>shivkumarm@drreddys.com</email>
      <country>India</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Shivkumar Madki, Dr. Reddy’s Laboratories (DRL)</name>
      <address>Survey No. 47, Bachupalli, Qutubullapur, R. R. Dist  500 090, Andhra Pradesh</address>
      <phone>+91-40-4464-4000</phone>
      <fax>+91-40-2304-1418</fax>
      <email>shivkumarm@drreddys.com</email>
      <country>India</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Connie Leggio</name>
      <address>Level 10, 606 St Kilda Road
Melbourne Victoria, 3004</address>
      <phone>+61 3 9519 6886</phone>
      <fax>+61 3 9519 6888</fax>
      <email>connie.leggio@quintiles.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>